By Denny Jacob
Danaher posted improved results across key metrics in its latest quarter, which it attributed to momentum in its bioprocessing unit and demand above expectations in its molecular diagnostics business.
The manufacturing conglomerate logged earnings of $954 million, or $1.32 a share, for the first quarter ended March 28, down from $1.09 billion, or $1.45 a share, in the prior-year period.
Stripping out certain one-time items, earnings came in at $1.88 a share. Analysts polled by FactSet had expected $1.63 a share.
Sales edged down to $5.74 billion from about $5.8 billion. Analysts polled by FactSet had expected $5.57 billion.
Chief Executive Rainer Blair said revenue, earnings and cash flow exceeded expectations, thanks to continued momentum in bioprocessing and better-than-expected respiratory demand in its molecular diagnostics business. He also noted that the macroeconomic backdrop has become more dynamic since the start of the year.
For the second quarter, Danaher forecast adjusted revenue to grow by low-single digits year-over-year. The company also guided for adjusted earnings per share of between $7.60 and $7.75 for 2025, in line with analysts' estimates.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 22, 2025 06:19 ET (10:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。